Interparfums header image

Interparfums

ITP

Equity

ISIN FR0004024222 / Valor 86977

Euronext - Euronext Paris (2025-11-19)
EUR 24.31-0.89%

Interparfums
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

Interparfums, Inc. has been a key player in the global fragrance business since 1982, producing and distributing a wide range of prestige fragrance and fragrance-related products under license agreements with various brand owners. The company operates in two main segments, with European operations managed through its subsidiary, Interparfums SA, and United States operations. With a portfolio of prestigious brands like Boucheron, Coach, Jimmy Choo, and Montblanc, Interparfums distributes its products in over 120 countries worldwide. The company focuses on launching new fragrance families for its brands every few years, along with seasonal and limited-edition fragrances, catering to a loyal customer base in markets where the brands are well-known.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (04.10.2025):

Interparfums reported record financial results for the fourth quarter of 2024, showcasing significant growth in net sales and earnings. The company achieved a diluted EPS of $5.12, surpassing expectations and reaffirmed its guidance for 2025. Additionally, Interparfums announced a 7% increase in its cash dividend, reflecting its strong financial performance and confidence in continued growth.

Record Net Sales

Interparfums reported net sales of $362 million for the fourth quarter of 2024, marking a 10% increase compared to the same period in 2023. This growth was broad-based across their portfolio, driven by strong demand for key brands globally.

Earnings Per Share Exceeds Expectations

The company achieved a diluted EPS of $5.12 in Q4 2024, up 8% from $4.75 in Q4 2023. Diluted EPS before impairment was $5.18, exceeding expectations and setting a new record for the company.

Reaffirmed 2025 Guidance

Interparfums reaffirmed its 2025 guidance, projecting net sales of $1.51 billion and EPS of $5.35, both representing a 4% increase. Despite economic uncertainties and foreign exchange impacts, the company remains confident in achieving its targets.

Increased Cash Dividend

The Board of Directors approved a 7% increase in the annual cash dividend rate to $3.20 per share, up from $3.00 per share, demonstrating continued confidence in the company's financial strength and growth prospects.

Summarized from source with an LLMView Source

Key figures

-32.7%1Y
-36.2%3Y
-17.3%5Y

Performance

29.8%1Y
30.4%3Y
31.8%5Y

Volatility

Market cap

2578 M

Market cap (USD)

Daily traded volume (Shares)

29,302

Daily traded volume (Shares)

1 day high/low

40.45 / 39.85

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Getinge AB
Getinge AB Getinge AB Valor: 84926
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.40%SEK 207.10
BridgeBio Pharma Inc
BridgeBio Pharma Inc BridgeBio Pharma Inc Valor: 48204826
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.96%USD 65.59
Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals PLC Jazz Pharmaceuticals PLC Valor: 14769757
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
6.13%USD 180.52
Intra-Cellular Therapies Inc
Intra-Cellular Therapies Inc Intra-Cellular Therapies Inc Valor: 23194616
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.00%USD 131.87
Denali Therapeutics Inc
Denali Therapeutics Inc Denali Therapeutics Inc Valor: 39149539
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.63%USD 17.48
AstraZeneca PLC
AstraZeneca PLC AstraZeneca PLC Valor: 982352
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.19%GBP 135.66
Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC Hikma Pharmaceuticals PLC Valor: 2324471
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.20%GBP 15.58
Spire Healthcare Group PLC
Spire Healthcare Group PLC Spire Healthcare Group PLC Valor: 24881418
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.55%GBP 2.23
National Healthcare Corp
National Healthcare Corp National Healthcare Corp Valor: 836282
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.75%USD 124.93
BrightSpring Health Services Inc
BrightSpring Health Services Inc BrightSpring Health Services Inc Valor: 131996976
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.61%USD 31.55